Tiny RNA helps tuberculosis bacteria survive inside immune cells

Tuberculosis remains a major global health threat caused by the bacterium Mycobacterium tuberculosis. Understanding how this microbe survives inside human immune cells is central to developing better ways to prevent and treat disease. In new work led by corresponding author Feng Ge, researchers set out to uncover molecular differences between a virulent laboratory strain, H37Rv, and a related attenuated strain, H37Ra, with the goal of finding small regulatory molecules that influence bacterial survival. The team focused on small non-coding RNAs (sRNAs), short pieces of RNA that do not code for proteins but can control bacterial genes and behaviour. To compare the two strains, they combined high-resolution protein measurements with RNA sequencing to map differences in protein levels and sRNA expression. This comparative approach was intended to reveal which bacterial pathways are altered in the more virulent strain and to identify candidate sRNAs that might change how the bacterium interacts with human immune cells.

To carry out the comparison, the researchers used label-free quantitative proteomics, parallel reaction monitoring, and sRNA-seq to measure proteins and sRNAs in H37Rv and H37Ra. Bioinformatic analysis of the proteomic data revealed that differentially expressed proteins were significantly enriched in pathways linked to lipid metabolism and fatty acid biosynthesis, processes already known to be connected to M. tuberculosis virulence. Among the sRNAs, they identified a novel small RNA named ASpks2 that was significantly downregulated in the virulent H37Rv strain. Functional validation experiments showed that ASpks2 directly targets the polyketide synthase gene pks2 and that this interaction modulates pks2 expression. Importantly, altering this sRNA–gene interaction affected bacterial survival in human macrophages THP-1 cells, demonstrating a functional link between the newly discovered sRNA ASpks2, pks2 regulation, and intracellular survival.

These findings identify a specific regulatory molecule and connect it to a biochemical pathway that supports bacterial survival inside immune cells. By correlating broad omics measurements with focused functional tests, the study pinpoints ASpks2 and its target pks2 as part of a regulatory network that contributes to M. tuberculosis virulence. The work provides fresh molecular insight into how lipid metabolism and fatty acid biosynthesis pathways are tied to survival in macrophages, through the action of an sRNA. While the results are at an early, laboratory stage, they offer a clearer picture of the bacterial strategies that help M. tuberculosis persist in human cells. According to the authors, including Feng Ge, the discovery of ASpks2 and its role in regulating pks2 may serve as a basis for the development of targeted therapies against tuberculosis and will likely guide follow-up research into sRNA-based regulation in this pathogen.